October 26, 2021
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
October 25, 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian ...
October 20, 2021
Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021
Alkermes worked with The Harris Poll to conduct a survey exploring drinking patterns during the COVID-19 pandemic and people’s motivations to seek help.
Senior Director and Research Oncology Program Lead Heather Losey, Ph.D. shares five leadership lessons she’s learned throughout her career as part of an Authority Magazine series highlighting inspirational women in STEM.
In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.